Aspirin for the Management of Endometriosis-associated Pelvic Pain
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Endometriosis-associated pelvic pain (EAPP) is common in endometriosis and pain control is an
important goal of long-term management. Non-steroidal anti-inflammatory drugs and oral
contraception are the two first line therapies for endometriosis. High quality study about
aspirin for the EAPP is absent. In this study, we hypothesis that aspirin is effective in
controlling EAPP. A randomized, open, and controlled study will be implemented. Patients with
EAPP with visual Analogue Scale(VAS）>30 mm will be included and low dose aspirin（75mg/day） be
prescribed. Yasmin(Drospirenone ethinyl estradiol tablet) will be used as positive control.
The primary efficacy end points is the reduction of the pain score of EAPP at 24th week
assessed with VAS score. Pelvic examination, sonography and blood test will be to performed
to evaluate the lesion and coagulation function. The adverse event and medication compliance
will be investigated. The aim of this study is to explore the efficacy and safety of low dose
aspirin therapy in management of EAPP. This study will provide new options for the long-term
management of endometriosis, which will help reduce the medical cost of endometriosis.
Phase:
Phase 4
Details
Lead Sponsor:
Women's Hospital School Of Medicine Zhejiang University
Treatments:
Aspirin Drospirenone Drospirenone and ethinyl estradiol combination Estradiol Ethinyl Estradiol